Showing results (281-290 of 305) with videos related to

Sort By:
Pageof 31
Scientific Reports|August 14, 2019
Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancerSumitra Mohan, Mahmood Ayub, Dominic G Rothwell, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|December 16, 2018
Phase-Dependent Suppression of Beta Oscillations in Parkinson's Disease PatientsAbbey B Holt, Eszter Kormann, Alessandro Gulberti, et al.
Cancers|August 27, 2021
Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?Melissa Frizziero, Alice Durand, Rodrigo G Taboada, et al.
British Journal of Cancer|June 22, 2018
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trialAlison C Backen, Andre Lopes, Harpreet Wasan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2017
Cancer Susceptibility Gene Mutations in Individuals With Colorectal CancerMatthew B Yurgelun, Matthew H Kulke, Charles S Fuchs, et al.
Frontiers in Endocrinology|June 24, 2021
The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine TumoursDaniel J Cuthbertson, Jorge Barriuso, Angela Lamarca, et al.
The Lancet Regional Health. Europe|May 19, 2025
Correction to "New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe" [The Lancet Regional Health - Europe, volume 50, March 2025, 101170]Lorenza Rimassa, Angela Lamarca, Grainne M O'Kane, et al.
The Lancet Regional Health. Europe|March 17, 2025
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across EuropeLorenza Rimassa, Angela Lamarca, Grainne M O'Kane, et al.
Future Oncology (London, England)|July 29, 2025
ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabineEleni Vrana, Hayley Timmins, Ashley Osborne, et al.
Eclinicalmedicine|June 8, 2023
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinomaMairéad G McNamara, Jayne Swain, Zoe Craig, et al.
Pageof 31